NS Partners Ltd Has $13.77 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

NS Partners Ltd increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.0% during the third quarter, Holdings Channel reports. The fund owned 208,641 shares of the medical research company’s stock after acquiring an additional 4,170 shares during the quarter. NS Partners Ltd’s holdings in Edwards Lifesciences were worth $13,768,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the first quarter worth $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences during the 2nd quarter worth about $29,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences during the 3rd quarter valued at about $32,000. Avior Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the period. Finally, Webster Bank N. A. purchased a new stake in shares of Edwards Lifesciences in the second quarter worth approximately $39,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock worth $2,657,000 in the last three months. 1.27% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $70.20 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market capitalization of $41.40 billion, a P/E ratio of 10.13, a P/E/G ratio of 3.81 and a beta of 1.12. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The business has a fifty day simple moving average of $67.59 and a two-hundred day simple moving average of $75.91.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the prior year, the business posted $0.59 earnings per share. The company’s revenue was up 8.9% on a year-over-year basis. On average, analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on EW shares. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Truist Financial lowered their price target on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a research note on Friday, October 25th. UBS Group dropped their price target on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 10th. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.